About CGTA

The Consortium for Genomics & Therapeutics in Africa (CGTA) has been established by the African Institute of Biomedical Science and Technology (AiBST) as a mechanism to implement its Bill and Melinda Gates (BMGF) Calestous Juma (CJ) Research Leadership award to Prof. Collen Masimirembwa. The two main aims of the award being to establish a drug discovery ecosystem and to expand pharmacogenomic testing for improved health in Africa. CGTA is a research network that aims to create an ecosystem for translational research in genomics and therapeutics to deliver healthcare solutions for Africa.

Our AIM

To enhance Africa’s capacity for drug discovery, development & deployment and to harness the power of genomics for improved health in Africa.

Objectives

To build capacity for bioanalytics, genomics, bioinformatics and pharmacometrics to support translational science at selected Centers of Excellence (CoE) in Africa through establishing advanced technology platforms and training highly skilled scientists.

To harness Africa’s genomic diversity in health research and innovation for drugs, vaccines, diagnostics and medical devices.

To expand the clinical application of pharmacogenomics through these CoE.

Prof. Collen Masimirembwa

Consortium Chairman

African Institute of Biomedical Science and Technology (AiBST), Zimbabwe

Dr.Tinashe Mazhindu

Co-Lead

African Institute of Biomedical Science and Technology (AiBST), Zimbabwe

Our Experts

Get closer with CGTA Team

Learn more about the Consortium for Genomics & Therapeutics in Africa (CGTA) Team